B. Riley restated their buy rating on shares of TG Therapeutics (NASDAQ:TGTX) in a research report sent to investors on Monday. They currently have a $21.50 price target on the biopharmaceutical company’s stock.
A number of other equities analysts have also recently issued reports on TGTX. BidaskClub upgraded shares of TG Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 24th. SunTrust Banks reiterated a buy rating and set a $28.00 price target on shares of TG Therapeutics in a report on Tuesday, October 3rd. ValuEngine downgraded shares of TG Therapeutics from a hold rating to a sell rating in a report on Monday, October 16th. Finally, HC Wainwright reiterated a buy rating and set a $33.00 price target (up from $18.00) on shares of TG Therapeutics in a report on Tuesday, November 14th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $25.50.
Shares of TG Therapeutics (NASDAQ:TGTX) traded up $0.15 on Monday, reaching $8.20. 1,070,500 shares of the company’s stock were exchanged, compared to its average volume of 1,540,540. TG Therapeutics has a one year low of $4.10 and a one year high of $15.35.
TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.05). The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. equities analysts expect that TG Therapeutics will post -1.86 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of TGTX. Legal & General Group Plc grew its holdings in shares of TG Therapeutics by 4.1% during the first quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 384 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of TG Therapeutics by 11.0% during the first quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 1,395 shares in the last quarter. BB&T Securities LLC grew its holdings in shares of TG Therapeutics by 63.0% during the second quarter. BB&T Securities LLC now owns 16,949 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 6,549 shares in the last quarter. First Mercantile Trust Co. grew its holdings in shares of TG Therapeutics by 199.7% during the second quarter. First Mercantile Trust Co. now owns 19,179 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 12,779 shares in the last quarter. Finally, Voya Investment Management LLC grew its holdings in TG Therapeutics by 40.2% in the second quarter. Voya Investment Management LLC now owns 22,521 shares of the biopharmaceutical company’s stock valued at $226,000 after purchasing an additional 6,463 shares during the period. Institutional investors and hedge funds own 50.45% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/14/b-riley-reaffirms-buy-rating-for-tg-therapeutics-tgtx.html.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.